ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
ViiV Health announces new packaging option now available in the U.S. for Dovato
After sparring with GSK’s ViiV Healthcare over the price of its HIV medication dolutegravir, Colombia appears to be taking matters into its own hands.
GSK’s ViiV Healthcare is eyeing 2026 and 2027 for potential longer-acting versions of its respective HIV injectables for prevention and treatment, executives said on a media call Wednesday.
PITTSBURGH and BANGALORE, India, Sept. 5, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced U.S. Food and Drug Administration (FDA) tentative approval for a New Drug Application for abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg tablets for oral suspension for the treatment of HIV-1 infection in paediatric patients.
ViiV Healthcare`s Dovato (dolutegravir, lamivudine) Receives Approval in Europe
Global pharma major Lupin Limited (Lupin) announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), dolutegravir tablets for oral suspension, 5 mg, to market a generic equivalent of Tivicay PD tablets for oral suspension, 5 mg of ViiV Healthcare Company. This product will be manufactured at Lupin’s Nagpur facility in India.
Lupin's Generic Dolutegravir Sodium Receives Approval in the U.S.
FDA Confirms Paragraph IV Patent Litigation for Abacavir Sulfate, Dolutegravir and Lamivudine Tablets
Pharmaceutical firm Lupin Ltd on Tuesday said it has received tentative approval from the US health regulator for its new drug application Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) tablets.